Dry Age-Related Macular Degeneration Market Size 2021: Market Growth, Demand, Trends, and Future Opportunity By 2026
Dry Age-Related Macular Degeneration Market
This
degenerative eye disease is caused by the thinning of the macula and interferes
with a clear vision in the elderly. The macula is part of the retina that
facilitates clear vision; when this part of the eye deteriorates, it causes
blurred or distorted vision. But this does not mean that the individual will
lose his or her sight, only the central vision is affected by this degenerative
disease, and the peripheral vision remains intact. Vision loss is slow and can
be corrected using innovative ocular treatments.
It has
been estimated that the Dry Age-Related Macular Degeneration Market has seen a jump due to increased research in drugs,
rising amount of COVID-19 cases among the old and age-restricted chronic
diseases.
List
of Key Companies Covered in this report:
Santen
Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada),
Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension
Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US),
Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South
Korea), Stealth Biotherapeutics Inc. (US)
Segment
Analysis
The
global dry
AMD market has been divided based on stages, age group, route of
administration, diagnosis& treatment, and end user.
The
market, based on stages, has been
segregated into early age-related macular degeneration, intermediate
age-related macular degeneration, and late age-related macular
degeneration.
Based
on age group, the dry AMD market has been divided into above 75 years, above 60
years, and above 40 years.
Based
on diagnosis & treatment, the dry
AMD market has been divided into treatment and diagnosis.
Treatment
type is further bifurcated into nutrition therapy and telescopic lens implant.
Nutrition therapy is again divided into antioxidants and others. Antioxidants
areal so segregated as vitamins, zinc, copper, omega-3 fatty acids, and others.
Diagnosis
is bifurcated into fluorescein angiogram, preliminary test, optical coherence
tomography, and others.
Based
on route of administration, the market
is bifurcated into oral, intravitreal, and others.
On
the basis of end user, the market is
bifurcated into hospitals and clinics, diagnostic centers, academic research
institutes, and others
Dry Age-Related Macular Degeneration Market
Size
AMD
has projected a rise from $ 1.58 billion in 2020 to $ 2.64 billion in 2026. The
CAGR rate is expected to grow exponentially between 2021 to 2018 – 8.93%.
Dry Age-Related Macular Degeneration Market
Share
It has
been reported by the American Academy of Ophthalmology that about 11 million
people over the age of fifty experience blindness as a result of AMD. Hence
making it a supple market for AMD related treatments. Obesity-related macular
degeneration is also on the rise in North America, along with high blood
pressure from an erratic lifestyle.
Advances
in research and development in Europe and Asia-Pacific have enabled more
patients to see more clearly. The African continent, particularly the Sahara
subcontinent, has experienced a significant increase in dry age-related macular
degeneration due to lack of vitamin A and poor dietary standards. Thus, making
this region the key player for pharmaceutical companies to invest in.
The
key companies that are invested into creating feasible solutions for AMD are
Pfizer, Bayer AG, Regenron Pharmaceutical Inc., GlaxoSmithKline plc, and
Novartis AG.
Dry Age-Related Macular Degeneration Market
Growth
The
AMD market is led by dry and wet drug solutions that treat this degenerative
disease. Wet age-related AMD will soon see a jump of 95% in the year 2022.
After the impact of COVID-19, it has been observed that wet macular
degeneration has affected most of the ageing population. In this type, there is
an atypical growth of blood vessels beneath the retina, causing it to bleed
create vision obstruction. Developed countries have introduced intraocular
anti-VEGF injections for patients suffering from wet AMD, thus increasing
treatment capacity globally.
In
recent years, Stargardt disease, a genetically inherited retinal disorder that
has become dominant among the younger population, has given impetus for
research towards macular degeneration drugs.
Lucentis,
Avastin, Eylea and Visudyne are some of the prominent drugs available in the
market to treat dry age-related macular degeneration. The Lucentis market has
grown rapidly in developed countries since the government introduced healthcare
benefits for the elderly through affordable treatments.
Dry Age-Related Macular Degeneration Market
Value
It has
been noted that off-label drugs are getting more popular due to their
affordability than on-label drugs to treat AMD. An off-label drug like Avastin
is sold rapidly in the market for patients who can get treated within their
income budget.
On a
case-by-case basis, the market is segmented into intravenous and intravitreous.
It is said that the intravitreal segment dominates the market because it is
most effective because of the targeted distribution of drugs. Furthermore, the
majority of anti-VEGF injections are given intravitreally or intraocular.
Industry News
Recent
data released by the World Bank statistics indicate that the older generation
living above 65% is rising. They represent approximately 8.873% of the
population, indicating that patients with AMD will increase due to chronic
diseases and diseases.
Market Research Future (MRFR)
enable customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New
York,
New York 10013
Comments
Post a Comment